Background. The c-mos proto-oncogene was one of the first proto-oncogenes to be cloned. Apart from its role in meiosis, many efforts have been made to illuminate the mechanisms by which c-mos acts as an oncogene. c-mos or its coding messenger RNA have been confirmed in most somatic tissues at low levels. However, a detailed role of c-mos as an oncogene in somatic cells remains unknown.
Background. The c-mos proto-oncogene was one of the first proto-oncogenes to be cloned. Apart from its role in meiosis, many efforts have been made to illuminate the mechanisms by which cmos acts as an oncogene. c-mos or its coding messenger RNA have been confirmed in most somatic tissues at low levels. However, a detailed role of c-mos as an oncogene in somatic cells remains unknown.
Methods. In this study, we analyzed online databases to find out the correlation between Mos expression and poor survival rates in human cancer patients. Then, we investigated whether the involvement of c-mos in tumor progression via applying Apc min intestinal cancer model and Kras G12D lung cancer model.
Results. First, we found the expression of Mos differed between human and mice, and a significant correlation between high Mos expression and poor survival rates in lung cancer
patients. Interestingly, we tested that the effects of deficient c-mos in both Apc min intestinal cancer model and Kras G12D lung cancer model. Despite the abovementioned significant correlation, the results did not show a strong inhibitory effect on murine models of lung and intestine tumors. We find no evidence of a direct role for c-mos in tumor progression in abovementioned mice models.
Discussion. It indicated that functions of c-mos gene might be species-specific and that c-mos involvement in tumor progression was circumstantial and it probably depended on other oncogene activation.
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Introduction
At the molecular level, emerging oncogene paradigm has been proved to be a powerful tool in answering the questions concerning the nature of tumorigenesis in human and laboratory animals. Proto-oncogenes, known as oncogenes in the non-activated state, probably regulate cell growth and differentiation. A direct evidence for the involvement of proto-oncogenes in cancer was that the behavior of retroviruses carrying activated oncogenes directly implicated in tumorigenesis in animal models.
One of the first proto-oncogenes to be cloned was the c-mos gene of which the product was Mos, a member of the serine/threonine kinase family (Oskarsson et al., 1980) . According to the previous study (Dupré et al., 2002) , as the synthesis of Mos was specifically regulated and restricted in time and cell types, the expression of Mos was hardly detected in somatic cells except in germ cells. Thus, much of the research concerning Mos has been focused on its role in meiosis. Mos is strictly necessary for the first meiotic division of oocytes and then regulates a critical checkpoint function during metaphase II (Sagata et al., 1989) . There are several comprehensive reviews available on this topic (Singh & Arlinghaus, 1997; Sagata, 1997; Yew, Strobel & Vande, 1993) .
During the past 30 years, many efforts have been made to illuminate the mechanisms by which c-mos acts as an oncogene. c-mos or its coding messenger RNA have been confirmed in most somatic tissues at low levels (Herzog et al., 1989; Propst et al., 1987; Li et al., 1993) .
Overexpression of c-mos has been found in 27% of human non-small cell lung carcinomas. (Gorgoulis et al., 2001) . c-mos is also the one of identified 18 kinase and kinase-related genes whose overexpression can substitute for EGFR in EGFR dependent lung adenocarcinomas (Sharifnia et al., 2014) . Lidereau et al. found the breast cancer patients had a higher percentage of polymorphism in the c-mos locus which caused the activation of the c-mos proto-oncogene in breast tumors (Lidereau et al., 1985) than the leukemia patients. Vitale et al. revealed that Mos was upregulated in colon cancer cells after spindle damage (Vitale et al., 2010) . Recent studies identified Mos pathway in human colorectal cancers (CRCs) (Centelles, 2012) and confirmed that
Mos-mitogen-activated protein kinase pathway was activated in irradiated p53-mutant lymphoma cells (Erenpreisa & Wheatley, 2005; Erenpreisa, Kalejs & Cragg, 2005) . Moreover, upregulation of Mos was observed in genotoxically stressed lymphoma and human breast cancer cell lines (Erenpreisa, Kalejs & Cragg MS,2005; Kalejs et al., 2006; Ianzini et al., 2009; Erenpreisa et al., 2009 ). However, a detailed role of c-mos as an oncogene in somatic cells remains unknown.
Herein, the study was aimed to investigate whether c-mos is involved in tumor progression.
We first took advantage of online databases and found the expression of Mos differed between human and mice. There was also a significant correlation between high Mos expression and poor survival rates in lung cancer patients. (n=5, male) mice were housed for 20 weeks, then mice were sacrificed in CO2 Rodent Euthanasia Chamber and intestine tissues were collected for histopathological examination.
Tumor number and tumor size were measured. All mice were monitored twice a week until endpoint time of the experiment. No animals were excluded from the analysis. 
Quantitative RT-PCR

Histopathological analysis
Histopathological analysis was performed according to our previous study [20, 21] . In short, after mice were sacrificed, lungs were inflated with 1 ml Bouin's solution (Sigma-Aldrich) at room temperature for 20 min and fixed in 20 ml 4% PFA at 4°C for 24 h. Fixed lung tissues were embedded in paraffin sectioned at 5 μm thickness for hematoxylin and eosin (HE) staining.
Correlation of Mos expression and patient survival in lung cancers
The Mos expression and overall survival data were obtained from Kaplan-Meier survival plotter datasets as of April 20, 2017. The high and low Mos (221367_at) expressers were grouped using an arbitrary cutoff percentile of 50% (966 for low Mos expressers, and 960 for high Mos expressers). The Mantel-Cox Log-Rank tests were done using the GraphPad Prism 7 software. The Mos expression and overall survival data were obtained from TCGA datasets (Nature 2012). The high and low Mos expressers were grouped using an arbitrary cutoff percentile of 50% (110 for low Mos expressers, and 109 for high Mos expressers). The Mantel-Cox Log-Rank tests were done using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA).
Correlation of mos expression and patient survival in colorectal cancers
Study design and Statistical analysis
Minimal group size for tumor progression studies was calculated using an online power calculator available from DSS Researcher's Toolkit with an α of 0.05 and power of 0.8. Animal groups were not blinded but randomized, and investigators were blinded to the tumor counting experiments. No samples or animals were excluded from the analysis. Hypothesis concerning the data which included normal distribution and similar variation between the experimental groups were examined for appropriateness before the conduct of statistical tests. All statistical analyses were performed with Student's t-test (two groups) or ANOVA (multiple groups) using SPSS version 21.0, software (IBM Corp, Armonk, NY).
Results
Mos expression from publicly available database
According to the publicly available BIOGPS database (http://www.biogps.org) records, cmos was found to be expressed almost evenly in human tissues (Fig 2A) , while it expressed significantly higher in ovaries than other tissues in mice (Fig 3D) .
Analysis of the TCGA Lung 2 cohort in the Oncomine database (www.oncomine.org)
showed that Mos expression was significantly upregulated in human lung adenocarcinoma samples than in the non-tumorous lung tissues (Fig 2B) . In addition, analysis of the datasets obtained from Kaplan-Meier survival plotter revealed there might be a significant correlation between high Mos expression and poor survival rates (Fig 3C) . The expression of Mos in human CRCs implicated that both human colon and rectal adenocarcinoma tissues had higher Mos expression (Fig 2D) , although the correlation of high Mos expression with poor survival rates was a very slight trend toward significance (Fig 2E) .
Genetic deletion of c-mos gene has no effect on intestine and lung morphogenesis
Before the establishment of the lung cancer and intestine tumor animal model, the c-mos deficiency was confirmed in both lung and small intestine tissues using Real-time PCR quantification ( Fig 3A) . Morphological changes of lung and small intestine in both Mos −/− and WT mice were observed at the age of 12 months. No significant differences were shown with regard to the tissue size, weight, and macroscopic appearance. The histological structures of lung and small intestine in Mos −/− and WT mice were nearly identical (Fig 3B and 3C ).
Genetic deletion of c-mos gene has no significant effect on tumor burden in Kras G12D mice
There was a trend on the slowdown of tumor progression in c-mos deficient mice, but it was not significant (Fig 4A-B) . Fig 3C showed Then, the role of mos-deficiency in tumor formation was investigated using the Apc Min/+ mouse intestinal tumor model. We found that there was no inhibitory effect on colon tumor progression when the c-mos gene was absent (Fig 4F-G) , and the absence of c-mos gene had no influence on small intestinal tumor burdens in Apc Min/+ mice neither (Fig 4D-E) .
Discussion
Although the c-mos gene has been known to be involved in the control of meiosis and mitosis for more than three decades (Herzog et al., 1989; Propst et al., 1987; Li et al., 1993) , our understanding of its protein product Mos and its role in somatic cells on the mechanisms by which Mos could act as an oncogene is still incomplete. Web-based databases and data-mining platforms such as BIOGPS and Oncomine have been proved as a powerful tool for the cancer research community (Rhodes et al., 2004) . In this study, we initially took advantage of these databases and found the expression of Mos in human differs from mice. In human, the expression of Mos was relatively even in different organs whilst Mos expression was higher in ovary than in other organs in mice. These results indicated that c-mos might have some species-specific effects.
The analysis also suggested that Mos expression was significantly upregulated in human lung adenocarcinoma samples than in the non-tumorous lung tissue with a significant correlation between high Mos expression and poor survival rates. Human colon and rectal adenocarcinoma tissues also had higher Mos expression with an apparent significant correlation between high Mos expression and poor survival rates. These results seemed to support that Mos might promote tumor progression. Given this, we first tested biological function of the c-mos gene in tumor progression in the Apc Min/+ mouse which was regarded as a good model to study multistage colon carcinogenesis (Yamada & Mori, 2007) . Besides, we also investigated the role of c-mos deficiency in the formation of lung tumors using the Kras G12D mice which was suggested as a classic model for the experimental study of lung cancer (Gao et al., 2010; Xiao et al., 2015) . No significant changes of the tissue size, weight, and macroscopic appearance were found in lung tissue in c-mos −/− mice via gross morphological observations. Regarding multiple driver oncogenes in human NSCLCs that included but not were limited to KRAS, EGFR, ALK, RET, BRAF, PIK3CA, MET, HER2, ROS1, MEK1, NRAS and AKT1, the concurrence patterns of c-mos expression with Kras, EGFR, TP53 and BRAF were found in this study, however, only the correlation with RET showed significant pattern. It suggested that the functions of c-mos in Kras, EGFR, TP53 or BRAF which drove NSCLCs could be substituted by other pathways in a compensating way.
Also, according to previous studies (Kohno et al., 2012; Lewis et al., 1998) , approximately 1.3% of lung tumors evaluated had chromosomal changes which led to the occurrence of RET gene fusion. These gene rearrangements occurred almost in the entire adenocarcinoma tumors. RET fusions had been found in tumors without other frequent driver oncogenes (e.g., EGFR, KRAS, and ALK) as well. Although RET fusions are confirmed to be oncogenic both in vitro and in vivo, the functional consequences of RET fusion related proteins in lung adenocarcinoma are still not fully understood. In addition, in human NSCLC, there is a connection between c-mos expression and p53 status, genomic instability and tumor kinetics. This indicated that c-mos might play an important role in RET-driven lung cancers via its gene rearrangements. The c-mos/MKK/ERK pathway has been linked to the cellular processes like growth and differentiation (Mansour et al., 1994; Benayoun et al., 1998; Sagata et al., 1998) . Given the diversity of pathways in colon cancers, and the fact that ERKs could be activated by numerous upstream signals (Mansour et al., 1994) , our observation might imply c-mos/ERK pathway could just be one of the alternative activation modes of the Ras/Raf/MEK/ERK pathway which participated in colorectal cancer progression. Our results also showed a variation in inhibitive effects of Mos between murine and human tumors which might be attributed to the speciesspecific differences. There was some substantiated evidence interpreted that Mos played different roles in different species. In Xenopus oocyte maturation, as an active component of a cytostatic factor, Mos was required for the activation of maturation promoting factor, germinal vesicle breakdown and the extrusion of the first polar body as well (Sagata et al., 1998) . In contrast, the phenotype of c-mos mutant mice suggested that Mos was needed to arrest developing oocytes in metaphase II only in murine species (Colledge et al., 1994; Hashimoto et al., 1994) . These data all indicated that functions of the c-mos gene might be species-specific. In that the mysteries of the human body still remained unraveled, we suspected that the functions of c-mos in us, humans, might be a vulnerable target for cancer induction but not in mice. 
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